{
    "nctId": "NCT03582865",
    "briefTitle": "Genetic Study of CYP2D6 Enzyme and Therapeutic Drug Monitoring of Tamoxifen",
    "officialTitle": "Genetic Study of CYP2D6 Enzyme and Therapeutic Drug Monitoring of Tamoxifen in Premenopausal Women With Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "Estimate the frequency of Cyp2D6*1 and *4 alleles in Egyptian patients maintained on tamoxifen (20 mg/day) for management of ER +ve breast cancer.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Premenopausal patients will be included in this study, with hormone receptor positive tumors.\n* The hormone receptor positive tumor is diagnosed by microscopic examination if \u2265 10% of the cells are positive for estrogen by immunohistochemistry analysis.\n* All patients with normal hepatic and renal function, aspartate aminotransferase and alanine aminotransferase (\u22642 upper normal limit) and serum creatinine (\u22641.2 mg/dl).\n\nExclusion Criteria:\n\n* Patients treated with other hormonal therapy, radiation or chemotherapy will be excluded from the study.\n* Pregnant or breast feeding women will be excluded from the study.\n* Patients who are taking drugs that are known to inhibit CYP2D6 activity as SSRIs will be excluded from the study.",
    "sex": "FEMALE",
    "minimumAge": "20 Years",
    "stdAges": "ADULT"
}